What does Palvella Therapeutics, Inc. do?
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN rapamycin, a novel, 3.9% anhydrous topical gel that is in Phase 3 clinical trial…
What is Palvella Therapeutics, Inc.'s P/E and P/B ratio?
Palvella Therapeutics, Inc. has a P/E ratio of -26.1 and a P/B ratio of 8.40.
What is Palvella Therapeutics, Inc.'s debt-to-equity ratio?
Palvella Therapeutics, Inc. has a debt-to-equity ratio of 0.10.
How much does Palvella Therapeutics, Inc. owe compared with what it owns?
Palvella Therapeutics, Inc. owes $0.14 for every $1 it owns (balance sheet Jun 2026), which is low.
What is Palvella Therapeutics, Inc.'s Positivity rank?
Palvella Therapeutics, Inc. is ranked #5,698 of 6,774 companies globally and #3,151 of 4,000 in United States on PositoAI, with a Positivity Score of 16,204.
Does Palvella Therapeutics, Inc. have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?
No active red flags (PosiRed) or yellow flags (PosiYellow) are currently on record for Palvella Therapeutics, Inc..
Where can I read the latest news about Palvella Therapeutics, Inc.?
Recent headlines about Palvella Therapeutics, Inc. from the last 30 days, with links to the original articles, are on its News page on PositoAI.
Does Palvella Therapeutics, Inc. have a PositoAI PosiShot or QR code?
Yes. A dated PosiShot of Palvella Therapeutics, Inc.'s current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.